FDA Clearance Tracker · P010012-S017
CONTAK CD AND RENEWAL CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS
Last checked: Nov 20, 2026Latest source record: Feb 6, 2004 (this decision)Source: openFDAMethods & limitations
Decided
Feb 6, 2004
Approved
Time to decision
85 days
Received Nov 13, 2003. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P010012-S017
- Device name
- CONTAK CD AND RENEWAL CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS
- Applicant
- Boston Scientific Corp
- Applicant location
- St Paul, MN
- Received
- Nov 13, 2003
- Decided
- Feb 6, 2004
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P010012
Device type
- Device type
- Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR CHANGES TO THE INDICATIONS FOR USE AND CLINICAL STUDY SECTION LABELING. THE DEVICES ARE INDICATED FOR: FOR ICDS (VENTAK PRX, MINI, VITALITY, VENTAK AV AND PRIZM): GUIDANT ICDS ARE INTENDED TO PROVIDE VENTRICULAR ANTITACHYCARDIA PACING AND VENTRICULAR DEFIBRILLATION FOR AUTOMATED TREATMENT OF LIFE THREATENING VENTRICULAR ARRHYTHMIAS. FOR VITALITY AVT:GUIDANT VITALITY AVT IS INTENDED TO PROVIDE VENTRICULAR ANTITACHYCARDIA PACING AND VENTRICULAR DEFIBRILLATION FOR AUTOMATED TREATMENT OF LIFE THREATENING VENTRICULAR ARRHYTHMIAS. THIS DEVICE IS ALSO INTENDED TO PROVIDE ATRIAL ANTITACHYCARDIA PACING AND ATRIAL DEFIBRILLATION TREATMENT IN PATIENTS WHO HAVE OR ARE AT RISK OF DEVELOPING ATRIAL TACHYARRHYTHMIAS.FOR CRT-DS (CONTAK CD AND RENEWAL):GUIDANT CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS (CRT-DS) ARE INTENDED TO PROVIDE VENTRICULAR ANTITACHYCARDIA PACING AND VENTRICULAR DEFIBRILLATION FOR AUTOMATED TREATMENT OF LIFE THREATENING VENTRICULAR ARRHYTHMIAS. GUIDANT CRT-DS ARE ALSO INDICATED FOR REDUCTION OF SYMPTOMS OF MODERATE TO SEVERE HEART FAILURE (NYHA III/IV) IN PATIENTS WHO REMAIN SYMPTOMATIC DESPITE STABLE, OPTIMAL HEART FAILURE DRUG THERAPY, AND HAVE LEFT VENTRICULAR DYSFUNCTION (EF <= 35%) AND QRS DURATION >= 120 MS.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
- WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology, WATCHMAN FLX Left Atrial Appendage Closure Device with DeliPMA supplement
P130013-S074 · Decided Jul 16, 2025 · 180 days after receipt · Panel Track
Device type: System, appendage closure, left atrial (NGV) · Cardiology
K243245 · Decided Oct 18, 2024 · 7 days after receipt
Device type: Unit, Cryosurgical, Accessories (GEH) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.